Metabolic dysfunction-associated steatotic liver disease and diabetes: Together against the heart
Authors:
- Matheus Henrique Gonçalves de SouzaMSMatheus Henrique Gonçalves de Souza
- Pedro Miguel Mattos NogueiraPNPedro Miguel Mattos Nogueira
- Cristiane Alves Villela-NogueiraCVCristiane Alves Villela-Nogueira
Open Access
- 27 September 2025
- journal article
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 17 (9)
Abstract
Cardiovascular events are the main cause of mortality in individuals with type 2 diabetes mellitus (T2DM) and also in those with metabolic dysfunction-associated steatotic liver disease (MASLD). In this editorial, we comment on the results of a meta-analysis published by Shetty et al that shows an addictive risk for cardiovascular events when both pathologies are together. Patients with MASLD and T2DM have the worst prognosis related to liver disease since they have a higher risk for metabolic dysfunction-associated steatohepatitis, disease progression, and hepatocarcinoma. The meta-analysis included 370013 participants and showed that, although with high heterogeneity, there is a higher prevalence of cardiovascular events in patients with T2DM when MASLD is diagnosed compared to those without MASLD. Hence, MASLD and T2DM may have a new interplay regarding cardiovascular outcomes in addition to the already known liver-related outcomes.Keywords
This publication has 31 references indexed in Scilit:
- The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic reviewHepatology, 2023
- Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 DiabetesNew England Journal of Medicine, 2021
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2021
- Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver DiseaseHepatology, 2021
- Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLDHepatology, 2020
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trialThe Lancet, 2019
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trialThe Lancet, 2018
- Type 2 diabetesThe Lancet, 2017
- Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2016
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 studyThe Lancet, 2016